Structural variants of IFNα preferentially promote antiviral functions

Blood

Volumn 118, Issue 9, 2011, Pages 2567-2577

  Vázquez, Nancy ^a   Schmeisser, Hana ^b   Dolan, Michael A ^b   Bekisz, Joseph ^b   Zoon, Kathryn C ^b   Wahl, Sharon M ^a  

^a NATIONAL INSTITUTE OF DENTAL AND CRANIOFACIAL RESEARCH   (United States)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3G; GAMMA INTERFERON; GAMMA INTERFERON RECEPTOR; INDOLEAMINE 2,3 DIOXYGENASE;

ANTIVIRAL ACTIVITY; ARTICLE; CELL COMMUNICATION; CONTROLLED STUDY; DRUG BINDING SITE; DRUG CYTOTOXICITY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN STRUCTURE; SIGNAL TRANSDUCTION; VIRUS REPLICATION;

EID: 80052439484     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-12-325027     Document Type: Article

References (50)

1. Richman D.D., Margolis D.M., Delaney M., Greene W.C., Hazuda D., Pomerantz R.J. The challenge of finding a cure for HIV infection. Science. 2009;323(5919):1304-1307.
2. Orenstein J.M., Fox C., Wahl S.M. Macrophages as a source of HIV during opportunistic infections. Science. 1997;276(5320):1857-1861.
3. Wahl S.M., Greenwell-Wild T., Peng G., Ma G., Orenstein J.M., Vazquez N. Viral and host cofactors facilitate HIV-1 replication in macrophages. J Leukoc Biol. 2003;74(5):726-735. (Pubitemid 38040349)
4. Brass A.L., Dykxhoorn D.M., Benita Y., et al. Identification of host proteins required for HIV infection through a functional genomic screen. Science. 2008;319(5865):921-926. (Pubitemid 351263756)
5. Bishop K.N., Holmes R.K., Sheehy A.M., Malim M.H. APOBEC-mediated editing of viral RNA. Science. 2004;305(5684):645. (Pubitemid 39006746)
6. Chiu Y.L., Greene W.C. The APOBEC3 cytidine deaminases: An innate defensive network opposing exogenous retroviruses and endogenous retroelements. Annu Rev Immunol. 2008;(26):317-353. (Pubitemid 351600379)
7. Barr S.D., Smiley J.R., Bushman F.D. The interferon response inhibits HIV particle production by induction of TRIM22. PLoS Pathog. 2008;4(2):e1000007.
8. Peng G., Greenwell-Wild T., Nares S., et al. Myeloid differentiation and susceptibility to HIV-1 are linked to APOBEC3 expression. Blood. 2007;110(1):393-400. (Pubitemid 47026861)
9. Peng G., Lei K.J., Jin W., Greenwell-Wild T., Wahl S.M. Induction of APOBEC3 family proteins, a defensive maneuver underlying interferon-induced anti-HIV-1 activity. J Exp Med. 2006;203(1):41-46.
10. Asmuth D.M., Murphy R.L., Rosenkranz S.L., et al. Safety, tolerability, and mechanisms of antiretroviral activity of pegylated interferon Alfa-2a in HIV-1-monoinfected participants: A phase II clinical trial. J Infect Dis. 2010;201(11):1686-1696.
11. Herbeuval J.P., Shearer G.M. HIV-1 immunopathogenesis: How good interferon turns bad. Clin Immunol. 2007;123(2):121-128. (Pubitemid 46590066)
12. Myint A.M., Schwarz M.J., Steinbusch H.W., Leonard B.E. Neuropsychiatric disorders related to interferon and interleukins treatment. Metab Brain Dis. 2009;24(1):55-68.
13. Wichers M.C., Koek G.H., Robaeys G., Verkerk R., Scharpe S., Maes M. IDO and interferon-alpha-induced depressive symptoms: A shift in hypothesis from tryptophan depletion to neurotoxicity. Mol Psychiatry. 2005;10(6):538-544. (Pubitemid 40897037)
14. Hashemi N., Rossi S., Navarro V.J., Herrine S.K. Safety of peginterferon in the treatment of chronic hepatitis C. Expert Opin Drug Saf. 2008;7(6):771-781.
15. Greenwell-Wild T., Vazquez N., Jin W., Rangel Z., Munson P.J., Wahl S.M. Interleukin-27 inhibition of HIV-1 involves an intermediate induction of type I interferon. Blood. 2009;114(9):1864-1874.
16. Hundsberger H., Verin A., Wiesner C., et al. TNF: A moonlighting protein at the interface between cancer and infection. Front Biosci. 2008;(13):5374-5386.
17. Hu R., Bekisz J., Schmeisser H., McPhie P., Zoon K. Human IFN-alpha protein engineering: The amino acid residues at positions 86 and 90 are important for antiproliferative activity. J Immunol. 2001;167(3):1482-1489. (Pubitemid 32703147)
18. Schroecksnadel K., Zangerle R., Bellmann-Weiler R., Garimorth K., Weiss G., Fuchs D. Indoleamine-2, 3-dioxygenase and other interferon-gammamediated pathways in patients with human immunodeficiency virus infection. Curr Drug Metab. 2007;8(3):225-236. (Pubitemid 46621672)
19. Boasso A., Hardy A.W., Anderson S.A., Dolan M.J., Shearer G.M. HIV-induced type I interferon and tryptophan catabolism drive T cell dysfunction despite phenotypic activation. PLoS One. 2008;3(8):e2961.
20. Murray M.F. Tryptophan depletion and HIV infection: A metabolic link to pathogenesis. Lancet Infect Dis. 2003;3(10):644-652. (Pubitemid 37210228)
21. Schmeisser H., Kontsek P., Esposito D., Gillette W., Schreiber G., Zoon K.C. Binding characteristics of IFN-alpha subvariants to IFNAR2-EC and influence of the 6-histidine tag. J Interferon Cytokine Res. 2006;26(12):866-876. (Pubitemid 46025676)
22. Roy A., Kucukural A., Zhang Y. I-TASSER: A unified platform for automated protein structure and function prediction. Nat Protoc. 2010;5(4):725-738.
23. Phillips J.C., Braun R., Wang W., et al. Scalable molecular dynamics with NAMD. J Comput Chem. 2005;26(16):1781-1802. (Pubitemid 43078511)
24. Brooks B.R., Brooks C.L. III, Mackerell A.D. Jr, et al. CHARMM: The biomolecular simulation program. J Comput Chem. 2009;30(10):1545-1614.
25. Gray J.J., Moughon S., Wang C., et al. Proteinprotein docking with simultaneous optimization of rigid-body displacement and side-chain conformations. J Mol Biol. 2003;331(1):281-299. (Pubitemid 36870793)
26. Chen H., Lilley C.E., Yu Q., et al. APOBEC3A is a potent inhibitor of adeno-associated virus and retrotransposons. Curr Biol. 2006;16(5):480-485. (Pubitemid 43343708)
27. Szebeni J., Dieffenbach C., Wahl S.M., et al. Induction of alpha interferon by human immunodeficiency virus type 1 in human monocyte-macrophage cultures. J Virol. 1991;65(11):6362-6364.
28. Yang C.H., Murti A., Pfeffer S.R., Fan M., Du Z., Pfeffer L.M. The role of TRAF2 binding to the type I interferon receptor in alternative NF kappaB activation and antiviral response. J Biol Chem. 2008;283(21):14309-14316.
29. Du Z., Wei L., Murti A., et al. Nonconventional signal transduction by type 1 interferons: The NFkappaB pathway. J Cell Biochem. 2007;102(5):1087-1094. (Pubitemid 350220030)
30. Platanias L.C. Mechanisms of type-I- and type-II-interferon- mediated signalling. Nat Rev Immunol. 2005;5(5):375-386. (Pubitemid 40685987)
31. Robinson C.M., Hale P.T., Carlin J.M. NF-kappa B activation contributes to indoleamine dioxygenase transcriptional synergy induced by IFN-gamma and tumor necrosis factor-alpha. Cytokine. 35(1-2):53-61, 2006. (Pubitemid 44485536)
32. Wen Z., Zhong Z., Darnell J.E., Jr. Maximal activation of transcription by Stat1 and Stat3 requires both tyrosine and serine phosphorylation. Cell. 1995;82(2):241-250.
33. Wang L., Tassiulas I., Park-Min K.H., et al. 'Tuning' of type I interferon-induced Jak-STAT1 signaling by calcium-dependent kinases in macrophages. Nat Immunol. 2008;9(2):186-193.
34. Nair J.S., DaFonseca C.J., Tjernberg A., et al. Requirement of Ca2+ and CaMKII for Stat1 Ser-727 phosphorylation in response to IFN-gamma. Proc Natl Acad Sci U S A. 2002;99(9):5971-5976. (Pubitemid 34493249)
35. Badley A.D., Dockrell D., Simpson M., et al. Macrophage- dependent apoptosis of CD4+ T lymphocytes from HIV-infected individuals is mediated by FasL and tumor necrosis factor. J Exp Med. 1997;185(1):55-64. (Pubitemid 27039440)
36. Kramer O.H., Heinzel T. Phosphorylation-acetylation switch in the regulation of STAT1 signaling. Mol Cell Endocrinol. 315(1-2):40-48, 2010.
37. Gupta S., Jiang M., Pernis A.B. IFN-alpha activates Stat6 and leads to the formation of Stat2:Stat6 complexes in B cells. J Immunol. 1999;163(7):3834-3841. (Pubitemid 29450909)
38. Yang C.H., Murti A., Pfeffer L.M. Interferon induces NF-kappa B-inducing kinase/tumor necrosis factor receptor-associated factor-dependent NF-kappa B activation to promote cell survival. J Biol Chem. 2005;280(36):31530-31536. (Pubitemid 41291896)
39. Chon S.Y., Hassanain H.H., Gupta S.L. Cooperative role of interferon regulatory factor 1 and p91 (STAT1) response elements in interferon-gamma- inducible expression of human indoleamine 2,3-dioxygenase gene. J Biol Chem. 1996;271(29):17247-17252. (Pubitemid 26244281)
40. Tas S.W., Vervoordeldonk M.J., Hajji N., et al. Noncanonical NF-kappaB signaling in dendritic cells is required for indoleamine 2,3-dioxygenase (IDO) induction and immune regulation. Blood. 2007;110(5):1540-1549. (Pubitemid 47443970)
41. Babcock T.A., Carlin J.M. Transcriptional activation of indoleamine dioxygenase by interleukin 1 and tumor necrosis factor alpha in interferon-treated epithelial cells. Cytokine. 2000;12(6):588-594. (Pubitemid 30453486)
42. Takikawa O. Biochemical and medical aspects of the indoleamine 2,3-dioxygenase-initiated L-tryptophan metabolism. Biochem Biophys Res Commun. 2005;338(1):12-19. (Pubitemid 41540531)
43. Zignego A.L., Cozzi A., Carpenedo R., et al. HCV patients, psychopathology and tryptophan metabolism: Analysis of the effects of pegylated interferon plus ribavirin treatment. Dig Liver Dis. 2007;39(Suppl 1):S107-S111 (Pubitemid 47528200)
44. Larrea E., Riezu-Boj J.I., Gil-Guerrero L., et al. Upregulation of indoleamine 2,3-dioxygenase in hepatitis C virus infection. J Virol. 2007;81(7):3662-3666. (Pubitemid 46456678)
45. Andersson J., Boasso A., Nilsson J., et al. The prevalence of regulatory T cells in lymphoid tissue is correlated with viral load in HIV-infected patients. J Immunol. 2005;174(6):3143-3147. (Pubitemid 40354012)
46. Boasso A., Herbeuval J.P., Hardy A.W., et al. HIV inhibits CD4+ T-cell proliferation by inducing indoleamine 2,3-dioxygenase in plasmacytoid dendritic cells. Blood. 2007;109(8):3351-3359. (Pubitemid 46572523)
47. Samikkannu T., Saiyed Z.M., Rao K.V., et al. Differential regulation of indoleamine-2,3-dioxygenase (IDO) by HIV type 1 clade B and C Tat protein. AIDS Res Hum Retroviruses. 2009;25(3):329-335.
48. Yeung M.C., Pulliam L., Lau A.S. The HIV envelope protein gp120 is toxic to human brain-cell cultures through the induction of interleukin-6 and tumor necrosis factor-alpha. AIDS. 1995;9(2):137-143.
49. Yadav A., Collman R.G. CNS Inflammation and Macrophage/Microglial Biology Associated with HIV-1 Infection. J Neuroimmune Pharmacol. 2009;4(4):430-447.
50. Ishiguro K., Green T., Rapley J., et al. Ca2+/calmodulin-dependent protein kinase II is a modulator of CARMA1-mediated NF-kappaB activation. Mol Cell Biol. 2006;26(14):5497-5508. (Pubitemid 44036215)